Comparative Pharmacology
Head-to-head clinical analysis: AVENTYL versus IMIPRAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVENTYL versus IMIPRAMINE HYDROCHLORIDE.
AVENTYL vs IMIPRAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nortriptyline, the active ingredient, inhibits the reuptake of norepinephrine and serotonin in the central nervous system, potentiating their effects. It also has anticholinergic and antihistaminergic properties.
Tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their synaptic concentrations. Also has anticholinergic, antihistaminergic, and alpha-1 adrenergic blocking effects.
Adults: 25 mg orally 3 to 4 times daily, maximum 150 mg/day.
Initial 75 mg/day orally in divided doses, increase to 150-200 mg/day; maximum 300 mg/day. For maintenance, 50-150 mg/day orally.
None Documented
None Documented
Terminal elimination half-life: 19-24 hours; requires 4-6 days to reach steady state.
Terminal half-life 11-25 hours (mean ~20 h); clinical context: steady-state achieved in ~1 week, dosing adjustment needed in hepatic impairment
Renal (30% as unchanged drug and metabolites); biliary/fecal (70% as metabolites)
Renal (70% as metabolites, <5% unchanged), biliary/fecal (30%)
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant